Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
Theodoros Karantanos,1 Ioannis Politikos,2 Vassiliki A Boussiotis3–5 1General Internal Medicine Section, Boston Medical Center, Boston University School of Medicine, Boston, MA, 2Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,...
Guardado en:
Autores principales: | Karantanos T, Politikos I, Boussiotis VA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a78f0932b2e542a597ae09502b0e554a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz C, et al.
Publicado: (2018) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale MB, et al.
Publicado: (2017) -
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
por: Illidge T, et al.
Publicado: (2012) -
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
por: Megías-Vericat JE, et al.
Publicado: (2019)